Drug Prices and FDA Rules: A Look at Recent Changes

For many Americans, the cost of medicine is a major concern. According to a recent poll by KFF Health News, about 60% of adults worry about paying for their prescription drugs, and more than 80% believe current prices are unreasonable. Because Americans often pay three times more for the same medicine than people in other countries, the government has been looking for ways to lower these costs.

Since the start of his second term, President Donald Trump has introduced several initiatives to address this issue. These include writing letters to drug companies to ask for lower prices, holding meetings with pharmaceutical leaders, and launching a website called TrumpRx. This site is designed to help people who pay with cash find cheaper medicine. Additionally, the administration has promised to speed up the approval process for biosimilars — which are cheaper, generic versions of expensive specialty drugs — by reducing the amount of government paperwork, often called "red tape," that companies must complete.

However, the actual impact of these actions is still unclear. KFF Health News reports that the details of these government negotiations remain hazy, and it is not always clear which drugs are covered by these new plans. Some experts are skeptical about the results. Aaron Kesselheim, a professor of medicine at Harvard Medical School, noted that these agreements often seem to be made for publicity rather than to create real change. He described the deals as "opaque" — meaning they are not clear or easy to understand — and difficult for the government to enforce.

Data from 46brooklyn, a consulting firm that tracks drug prices, supports the idea that costs are not falling as promised. The firm found that nearly 1,000 brand-name drugs increased in price in January 2026. Furthermore, 2025 saw the highest number of list price increases in history. Antonio Ciaccia, a co-founder of the firm, stated that these price hikes are "business as usual" rather than a sign of a new, cheaper era for patients. For example, in the first week of 2026, Pfizer raised the prices of 71 drugs by an average of 5% while lowering the price of only one.

While some patients might benefit from these programs, others may find better prices through their own insurance plans or existing discount programs. Mark Cuban, a billionaire investor who started his own company to sell low-cost generic drugs, said that even small changes can help individual patients. However, he noted that his own business model focuses on removing middlemen to keep costs low, which is a different approach than the government's current strategy.

In addition to pricing issues, the government is also facing challenges regarding how it approves new medicines. Recently, the Food and Drug Administration (FDA) made a significant change in its position on a rare cancer treatment. According to STAT News, the FDA had originally rejected a drug called Ebvallo in January, claiming that the clinical trial data provided by the companies Pierre Fabre Pharmaceuticals and Atara Biotherapeutics was not enough to prove the drug worked.

After a meeting in late April, the agency changed its mind. STAT News reports that the FDA now agrees that the completed study is sufficient to support a review of the drug. This decision comes after the departure of Vinay Prasad, who led the FDA’s Center for Biologics Evaluation and Research at the time of the initial rejection. This case highlights how the relationship between government regulators and drug companies can shift, affecting which treatments become available to patients.

Looking ahead, it remains to be seen whether these government efforts will lead to lower costs for the average person. While the administration continues to promote its initiatives, the pharmaceutical industry continues to raise list prices on many products. For now, patients are left to navigate a complex system where promises of cheaper medicine often clash with the reality of rising costs and changing regulations.